GPT and metabolic dysfunction-associated steatotic liver disease: Similarly, Li et al. evaluated the effect of 17 weeks of OEA administration (5 mg/kg/day, ip) on nonalcoholic fatty liver disease (NAFLD) in Sprague Dawley rats and found that the treatment with OEA delayed the progression of NAFLD by regulating plasma TG and cholesterol levels and reducing ALT, AST, and inflammatory liver cytokines compared with controls [45].